$385 Million is the total value of Avoro Capital Advisors LLC's 36 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
SRPT | New | SAREPTA THERAPEUTICS -INC | $15,060,000 | – | 469,025 | +100.0% | 3.92% | – |
AEGR | New | AEGERION PHARMACEUTICALS INC | $10,966,000 | – | 806,300 | +100.0% | 2.85% | – |
DERM | New | DERMIRA INC | $8,478,000 | – | 363,250 | +100.0% | 2.20% | – |
SPPI | New | SPECTRUM PHARMACEUTICALS INC | $7,867,000 | – | 1,315,600 | +100.0% | 2.04% | – |
NK | New | NANTKWEST- INC | $7,301,000 | – | 728,887 | +100.0% | 1.90% | – |
EGLTQ | New | EGALET CORPORATION. | $5,807,000 | – | 440,606 | +100.0% | 1.51% | – |
IWM | New | ISHARES RUSSELL 2000 ETFput | $4,979,000 | – | 1,280,000 | +100.0% | 1.29% | – |
SRPT | New | SAREPTA THERAPEUTICS -INCcall | $1,237,000 | – | 178,300 | +100.0% | 0.32% | – |
CBIO | New | CATALYST BIOSCIENCES INC. | $391,000 | – | 83,901 | +100.0% | 0.10% | – |
HRTX | New | HERON THERAPEUTICS INCcall | $153,000 | – | 500,000 | +100.0% | 0.04% | – |
KITE | New | KITE PHARMA INC.put | $113,000 | – | 26,000 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-13
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
ARGENX SE | 26 | Q3 2023 | 9.5% |
IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G/A | 2024-04-23 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.